J.B. Auliac - Concepedia

Author

J.B. Auliac

Also Known As

J-B. Auliac, J. Auliac, J. B. Auliac, J.-B. Auliac, J.B Auliac, J.B. Auliac, JEAN-BERNARD AULIAC, Jean Bernard Auliac, Jean Bernard. Auliac, Jean-Bernard Auliac

138

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Hôpital Intercommunal de Créteil Inserm Centre François Baclesse Centre Hospitalier Régional Universitaire de Brest Hôpital Nord

About

J.B. Auliac is an author at Hôpital Intercommunal de Créteil specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	897
2	Health Sciences	3	3	416
3	Immunology	3	3	81
4	Geriatrics	1	1	12
5	Nephrology	1	1	18

J.B. Auliac

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study R. Corre, Laurent Greillier, H. Le Caer, Journal of Clinical Oncology	2016	401
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study Alice Tison, Gilles Quéré, L. Misery, Arthritis & Rheumatology	2019	303
Follow-up of Bronchial Precancerous Lesions and Carcinoma <i>in Situ</i> Using Fluorescence Endoscopy S. Bota, J.B. Auliac, Christophe Paris, American Journal of Respiratory and Critical Care Medicine Interventional PulmonologySevere DysplasiaOncologic ImagingPathologyEndoscopic Imaging	2001	209
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01) C. Chouaïd, C. Dujon, Pascal Dô, Lung Cancer Surgical OncologyReal-world SettingHealth SciencesCancer DetectionMedicine	2014	187
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial Nathalie Baize, I. Monnet, Laurent Greillier, The Lancet Oncology Second-line TreatmentMedicinePathologyBronchial NeoplasmCancer Treatment	2020	145
Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies D. Debieuvre, Olivier Molinier, L. Falchero, The Lancet Regional Health - Europe	2022	68
Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients Olivier Molinier, François Goupil, D. Debieuvre, Respiratory Medicine and Research Prognostic FactorsFive-year SurvivalMedicinePathologyBronchial Neoplasm	2019	44
Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors K. Saboundji, J.B. Auliac, Maurice Pérol, Targeted Oncology Leptomeningeal MetastasesMedicineEgfr-tyrosine Kinase InhibitorsPharmacologyPathology	2018	43
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation J.B. Auliac, M. Pérol, David Planchard, Lung Cancer Pretreated PatientsOncologyReal-life EfficacyPathologyBronchial Neoplasm	2018	38
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study Fabrice Barlési, A. Dixmier, D. Debieuvre, OncoImmunology	2020	38

Page 1